Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Items 401–500 of 1,000
Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges
Reinius, M., & Smyth, E. C. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.3 · Cited by 14
Long, Q., Li, X., Wu, G., Zhang, J., & Li, H. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1156 · Cited by 14
“Numerous randomized controlled trials (RCTs) have revealed a significant increase in progression free survival (PFS) and overall survival (OS) with the addition of CDK4/6Is to ET (5-7).”
BackgroundLiu, Y., Wang, X., Zeng, X., Wu, Y., Liu, X., Tan, J., & Li, X. (2022) · Open Medicine · doi:10.1515/med-2022-0510 · Cited by 15
“crine therapy, lead to significantly longer overall survival (OS) compared with endocrine therapy alone in patients with advanced-stage breast cancer [4].”
BackgroundAwada, A. H., Gligorov, J., Jérusalem, G., Preusser, M., Singer, C. F., & Zielinski, C. C. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000565 · Cited by 14
Mavratzas, A., & Marmé, F. (2021) · Breast Care · doi:10.1159/000514561 · Cited by 14
Slomovitz, B. M., Weroha, S. J., Deng, W., Chon, H. S., Podder, V., Vogel, M. T. J., Backes, F. J., Thomas, E. D., Chen, L.-M., Tenney, M. E., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01348 · Cited by 17
Barrios, C. H., Freitas‐Júnior, R., Martins, S. J., Bines, J., Estevez-Diz, M. D. P., & Caleffi, M. M. (2021) · JCO Global Oncology · doi:10.1200/go.20.00566 · Cited by 16
Sanò, M. V., Martorana, F., Lavenia, G., Rossello, R., Prestifilippo, A., Sava, S., Ricciardi, G. R. R., & Vigneri, P. G. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2052277 · Cited by 16
“inhibitor with a consistently significant OS advantage in the first line setting for both pre- (MONALEESA-7) and postmenopausal (MONALEESA-2) breast cancer patients but also in the second-line setting (MONALEESA-3) [31,34].”
BackgroundInfluentialZhao, M., Hanson, K. A., Zhang, Y., Zhou, A., & Cha-Silva, A. S. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00957-7 · Cited by 14
Young Women with Breast Cancer: The Current Role of Precision Oncology
Srikanthan, A., Awan, A. A., McGee, S. F., & Rushton, M. K. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111620 · Cited by 14
“CDK 4/6 inhibitors in combination with endocrine therapy (e.g., aromatase inhibitors +/ − ovarian suppression) are now the standard of care in the first line setting for these patients, with data showing definitive survival benefits in young pre-and peri-menopausal females with this approach [69,70].”
BackgroundTong, F., Lu, Y., Ma, H., & Shen, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31583 · Cited by 14
“Im et al. found that Ribociclib + ET can improve the OS of HR + /HER2 breast cancer, and no new AREs were found [16].”
BackgroundSelf-citationMa, L., Yang, B., & Wu, J. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102770 · Cited by 14
Kimmick, G. G., Pilehvari, A., You, W., Bonilla, G., & Anderson, R. T. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07415-6 · Cited by 15
Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer
Bjerrum, A., Henriksen, A. F., Knoop, A. S., Berg, T., Tuxen, I. V., Lassen, U., & Petersen, T. S. (2024) · BJC Reports · doi:10.1038/s44276-024-00108-z · Cited by 14
Ferrari, P., Schiavone, M. L., Scatena, C., & Nicolini, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073438 · Cited by 18
Liu, X., Huang, J., Xie, Y., Zhou, Y., Wang, R., & Jian, L. (2019) · Medical Science Monitor · doi:10.12659/msm.918384 · Cited by 13
Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer
Tesch, H., Müller, V., Wöckel, A., Ettl, J., Belleville, E., Schütz, F., Hartkopf, A. D., Thill, M., Huober, J., Fasching, P. A., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1270-7481 · Cited by 13
Guarneri, V., Giorgi, C. A., Cinieri, S., Bengala, C., Mariani, G., Bisagni, G., Frassoldati, A., Zamagni, C., Rossi, C. D., Amoroso, V., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.008 · Cited by 13
Lee, J., Kim, S. H., Kang, B. J., Lee, A., Park, W. C., & Hwang, J.-W. (2021) · Scientific Reports · doi:10.1038/s41598-021-99600-6 · Cited by 15
Alzahrani, M. J., Stober, C., Liu, M., Awan, A. A., Ng, T. L., Pond, G. R., Alshamsan, B., Vandermeer, L., & Clemons, M. J. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06714-8 · Cited by 15
“Indeed, increasingly one has to question how these agents should be used as the balance between SSE prevention and BMA-related toxicity may change with time [29, 30].”
BackgroundAdjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Agostinetto, E., Arecco, L., & de Azambuja, E. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00250-7 · Cited by 14
Cardoso, F., Cella, D. F., Velikova, G., Harmer, V., Schumacher-Wulf, E., Rihani, J., Casas, A., & Harbeck, N. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102321 · Cited by 13
Self-citationAbate, A., Rossini, E., Tamburello, M., Laganà, M., Cosentini, D., Grisanti, S., Fiorentini, C., Tiberio, G. A. M., Scatolini, M., Grosso, E., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab248 · Cited by 14
D’Amico, P., & Cristofanilli, M. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00707 · Cited by 14
“This result was also achieved in the group of patients carrying PIK3CA or TP53 mutations.38 Conversely, in the three randomized trials that led to the approval of ribociclib, 26 patients who had a RB1 mutation detected in the baseline ctDNA did not benefit from the administration of ribociclib in addition to ET.7,8,39…”
BackgroundJi, Y., Yartsev, V., Quinlan, M., Serra, P., Wang, Y., Chakraborty, A., & Miller, M. C. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01206-2 · Cited by 13
Rugo, H. S., Harmer, V., O’Shaughnessy, J., Jhaveri, K. L., Tolaney, S. M., Cardoso, F., Bardia, A., Maheshwari, V. K., Tripathi, S., Haftchenary, S., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231152843 · Cited by 13
Self-citationMlinarić, Z., Turković, L., & Sertić, M. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.464698 · Cited by 12
Buqué, A., Bloy, N., Petroni, G., Jiménez‐Cortegana, C., Sato, A., Iribarren, C., Yamazaki, T., Galassi, C., Hensler, M., Bhinder, B., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae329 · Cited by 12
Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer
Kamaraju, S., Fowler, A. M., Weil, E., Wisinski, K. B., Truong, T. H., Lehr, M., Chaudhary, L. N., Cheng, Y. C., Chitambar, C. R., Rui, H., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab060 · Cited by 12
Buehler, A. M., Castilho, G., Dionne, P.-A., & Stefani, S. D. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211000593 · Cited by 14
Jeong, H., Jeong, J. H., Kim, J. E., Ahn, J., Jung, K. H., & Kim, S. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.205 · Cited by 12
Self-citationMoving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer
Palleschi, M., Tedaldi, G., Sirico, M., Virga, A., Ulivi, P., & Giorgi, U. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157884 · Cited by 14
“hibitors? Given the increased OS associated with the latter combination [83,127,128], this is probably the most reasonable option.”
BackgroundTwelves, C. J., Bartsch, R., Ben-Baruch, N. E., Borštnar, S., Dirix, L. Y., Tesařová, P., Timcheva, C. V., Zhukova, L., & Pivot, X. B. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.10.007 · Cited by 13
Bui, T. B. V., Burgering, B. M. T., Goga, A., Rugo, H. S., & Veer, L. V. ‘. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00473 · Cited by 15
Canino, F., Piacentini, F., Omarini, C., Toss, A., Barbolini, M., Vici, P., Dominici, M., & Moscetti, L. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137079 · Cited by 13
Brufsky, A., Liu, X., Li, B. C., McRoy, L., & Layman, R. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.865292 · Cited by 12
“A subgroup analysis of patients with pre/perimenopausal HR+/ HER2− advanced breast cancer with liver or lung metastasis who enrolled in theMONALEESA-7 trial demonstrated that ribociclib in combination with ET provided an OS benefit compared with placebo plus ET, although the results did not reach statistical significa…”
ResultBaş, O., Erul, E., Güven, D. C., & Aksoy, S. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07320-y · Cited by 16
Loft, M., Lok, S. W., BOER, R. D., Malik, L., Greenberg, S., Yeo, B. J., Anton, A., Nottage, M. K., Wong, V., Nott, L. M., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06856-1 · Cited by 12
Xie, N., Qin, T., Ren, W., Yao, H., Yu, Y., & Hong, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s254365 · Cited by 16
Kern, R., Corrêa, S., Scandolara, T. B., da Silva, J. C., Pires, B. R. B., & Panis, C. (2020) · Personalized Medicine · doi:10.2217/pme-2020-0070 · Cited by 15
Huang, W., & Wang, H. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-52 · Cited by 14
“21037/tbcr-20-52 MONALEESA-7 (14) and MONARCH 2 (Table 1) (15).”
InfluentialTherapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer
Schneeweiß, A., Bauerfeind, I., Fehm, T. N., Janni, W., Thomssen, C., Witzel, I., Wöckel, A., Müller, V., & on behalf of the Commission Breast of the Working Group Gynecologic Oncology (AGO) (2020) · Breast Care · doi:10.1159/000511925 · Cited by 12
Arndt, C., Tunger, A., Wehner, R., Rothe, R., Kourtellari, E., Luttosch, S., Hannemann, K., Koristka, S., Loureiro, L. R., Feldmann, A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.970457 · Cited by 12
“This kind of therapy has shown clinical efficacy by prolonging PFS and OS (Finn et al., 2016a; Cristofanilli et al., 2016; Hortobagyi et al., 2016; Im et al., 2019; Johnston et al., 2020; Slamon et al., 2020; Sledge et al., 2020).”
BackgroundTailoring therapies to counter the divergent immune landscapes of breast cancer
Attalla, S. S., Taifour, T., & Muller, W. J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1111796 · Cited by 16
“CDK4/6 inhibition in combination with aromatase inhibitors or ER modulators (such as letrozole and fulvestrant) is currently emerging as the standard of care for HR+ breast cancers due to improved patient survival in clinical trials (Im et al., 2019; Slamon et al., 2020).”
BackgroundGalvin, A., Courtinard, C., Bouteiller, F., Gourgou, S., Dalenc, F., Jacot, W., Arnedos, M., Bailleux, C., Dieras, V. C., Petit, T., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113422 · Cited by 11
Ribociclib in Breast Cancer Brain Metastases: A Case Report
Radke, I., von Wahlde, M., Schülke, C., & Tio, J. (2019) · Breast Care · doi:10.1159/000504405 · Cited by 11
Bertho, M., Patsouris, A., Augereau, P., Robert, M., Frenel, J., Blonz, C., & Campone, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1844662 · Cited by 11
Migliaccio, I., Leo, A., Galardi, F., Guarducci, C., Fusco, G. M., Benelli, M., Leo, A. D., Biganzoli, L., & Malorni, L. (2021) · Cancers · doi:10.3390/cancers13112640 · Cited by 12
The management of HER2‐positive early breast cancer: Current and future therapies
Chen, J., Colosimo, M. L., & Lim, E. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13655 · Cited by 12
Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer
Decker, J. T., Ma, J. A., Shea, L. D., & Jeruss, J. S. (2021) · Cancers · doi:10.3390/cancers13215343 · Cited by 13
“Similar results were observed for overall survival endpoints in this study [47].”
ResultRen, X., Yan, C., Tian, L., & Cui, X. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320221145520 · Cited by 13
Tibau, A., Martínez, M. T., Ramos, M., de la Cruz‐Merino, L., Santaballa, A., O’Connor, M., Martínez-Jáñez, N., Moreno, F., Fernández, I., Virizuela, J. A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148921 · Cited by 13
Tokunaga, E., Miyoshi, Y., Dozono, K., Kawaguchi, T., & Toi, M. (2023) · The Oncologist · doi:10.1093/oncolo/oyad301 · Cited by 11
Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer
Schlam, I. M., Giordano, A., & Tolaney, S. M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2288147 · Cited by 12
“At a median follow-up of 53.5 months, the mPFS was 28.3 vs. 13 months (HR 0.55, 95% CI 0.44–.69, p < 0.001), favoring the CDK4/6 inhibitor arm; the mOS was 58.7 vs. 48 months (HR 0.76, 95% CI 0.61–0.96, p < 0.001) [18,19].”
InfluentialMartínez-Jáñez, N., Bellet, M., Sànchez, L. M. M., Henao, F., Antón-Torres, A., Morales, S. M., Tolosa, P., Gil, V. L. O., Gimeno, T. S., Conejero, R. A., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07287-w · Cited by 12
“Overall survival was significantly longer in the ribociclib group than in the placebo group, with a 29% lower risk of death (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95) [ 22 ].”
BackgroundInfluentialMarinelli, O., Romagnoli, E., Maggi, F., Nabissi, M., Amantini, C., Morelli, M. B., Santoni, M., Battelli, N., & Santoni, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07619-1 · Cited by 13
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
Stellato, D., Thabane, M. E., Eichten, C., & Delea, T. E. (2021) · Current Oncology · doi:10.3390/curroncol28010051 · Cited by 14
Zhang, L., Song, G., Shao, B., Xu, L., Xiao, Y., Wang, M., Sumou, I. K., Zhang, Y., Liang, X., Jiang, H., et al. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001210 · Cited by 12
Nerone, M., Rossi, L. A., Condorelli, R., Ratti, V., Conforti, F., Palazzo, A., & Graffeo, R. (2023) · Cancers · doi:10.3390/cancers15133305 · Cited by 10
Luo, C., Yu, K., Luo, X., Lian, T., Liu, X., Wang, X., & Jin, Z. (2024) · BMC Cancer · doi:10.1186/s12885-024-12782-w · Cited by 12
Baun, C., Olsen, B. B., Alves, C. L., Ditzel, H. J., Terp, M. G., Hildebrandt, M. G., Poulsen, C. A., Gé, L. G., Gammelsrød, V. S., Orlova, A., et al. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108961 · Cited by 11
Jia, C., Zhang, S., Wang, J., Feng, B. C., Shi, F., Wang, M., Li, S., Xu, H., & Wang, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-97504-3 · Cited by 12
Johnson, K. C., Tien, A., Jiang, J., McNamara, J., Chang, Y.-W., Montgomery, C., DeSantis, A., Elena, L., Fujita, Y., Kim, S., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf257 · Cited by 13
Melanoma: Pathogenesis and Targeted Therapy
Fu, Y., Liu, J., Mo, Z., Wang, B., Deng, Y., & Jiang, Y. (2026) · MedComm · doi:10.1002/mco2.70566 · Cited by 14
“In clinical, several CDK4/6 inhibitors, including PD0332991 (palbociclib), LEE011 (riboci-clib), and LY2835219 (abemaciclib), were approved by US FDA for antitumor therapy [ 261–266 ].”
Raghavendra, A. S., Damodaran, S., Barcenas, C. H., Fuqua, S. A. W., Layman, R. M., & Tripathy, D. (2026) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70055 · Cited by 23
“118,127,132 It is important to note that survival benefits are difficult to compare among the different agents because this outcome was not the primary end point, and the studies enrolled different populations, particularly with various prior treatments in the metastatic setting.”
Self-citationThe CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
Gonçalvès, A., Finetti, P., Birnbaum, D., & Bertucci, F. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00256-2 · Cited by 10
Cui, Z. L., KADZIOLA, Z. A., Lipkovich, I. A., Faries, D. E., Sheffield, K. M., & Carter, G. C. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0230 · Cited by 11
Moore, H. C. F., Barlow, W. E., Somlo, G., Gralow, J. R., Schott, A. F., Hayes, D. F., Kühn, P., Hicks, J. B., Welter, L. M., Dy, P. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3131 · Cited by 10
Self-citationA Review of Current treatment for Triple-Negative Breast Cancer (TNBC)
Wahyuni, W., Diantini, A., Ghozali, M., & Sahidin, I. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00068 · Cited by 11
Villacampa, G. J., Falato, C., Paré, L., Hernándo, C., Arumí, M., Saura, C., Melis, G. G., Muñoz-Mateu, M., Gil‐Gil, M., Izarzugaza, Y., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.028 · Cited by 11
Park, S. Y., Suh, K. J., Lee, D., Ryu, H. S., Kim, M., Kim, S. H., Lee, K.-H., Kim, T., Kim, J. H., Park, I. A., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06566-8 · Cited by 12
Self-citationDecker, T. W., Lüdtke-Heckenkamp, K., Melnichuk, L., Hirmas, N., Lübbe, K., Zahn, M., Schmidt, M., Denkert, C., Lorenz, R., Müller, V., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.08.007 · Cited by 10
MPA/DMBA-driven mammary carcinomas
Buqué, A., Pérez-Lanzón, M., Petroni, G., Humeau, J., Bloy, N., Yamazaki, T., Sato, A., Kroemer, G., & Galluzzi, L. (2020) · Methods in cell biology · doi:10.1016/bs.mcb.2020.08.003 · Cited by 14
The prognosis of early-stage breast cancer in extremely young female patients
Chung, W., Lee, K., Chen, Y., Hsu, Y., Loh, Z.-J., Huang, C.-C., & Hsu, H. (2021) · Medicine · doi:10.1097/md.0000000000024076 · Cited by 10
Self-citationPosielski, N. M. (2022) · ONCOLOGY · doi:10.46883/2022.25920939 · Cited by 10
Chou, Y., Wang, C., Hsu, L., Chuang, P., Cheng, C., Li, N., Chen, C., Chen, C., Lai, Y., & Yen, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.5390 · Cited by 12
Roy, T., Barrows, E. D., Mainor, C. B., Collins, J. M., Lynce, F. C., Isaacs, C. J., & Pohlmann, P. R. (2023) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2023.101110 · Cited by 11
Kim, J., Shin, J., Ahn, J. S., Park, Y. H., & Im, Y. (2023) · Cancers · doi:10.3390/cancers15133431 · Cited by 10
Verret, B., Bottosso, M., Hervais, S., & Pistilli, B. (2022) · Cancers · doi:10.3390/cancers14174203 · Cited by 13
Goh, E., Labelle, S., & Chan, A. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231179190 · Cited by 9
Lorman-Carbó, N., Martínez‐Sáez, O., Fernández-Martínez, A., Galván, P., Chic, N., García-Fructuoso, I., Rodríguez, A., Gómez-Bravo, R., Schettini, F., Blasco, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67126-2 · Cited by 11
Comprehensive review of non-invasive-treatment-related cardiovascular toxicity in breast cancer
Li, C., Dai, H., Guo, X., Zhou, L., & Jiang, M. (2025) · iScience · doi:10.1016/j.isci.2025.111759 · Cited by 12
Rugo, H. S., Bardia, A., Gradishar, W. J., Hamilton, E. P., Hurvitz, S. A., Jhaveri, K. L., Mahtani, R. L., & Tolaney, S. M. (2025) · The Breast · doi:10.1016/j.breast.2025.104485 · Cited by 9
Self-citationLiu, P.-Y., Chang, W., & Wu, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218078 · Cited by 9
Abdel‐Razeq, H., & Sharaf, B. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s356757 · Cited by 10
“Recently published data have shown significant improvement in overall survival (OS), too.(21,22) Such dramatic improvements in treatment outcomes were seen in both premenopausal,(23,24) and”
BackgroundKim, S., Kim, M. H., Park, S., Kim, G. M., Kim, J. H., Kim, J. Y., Park, H. S., Park, S., Park, B., Kim, S. I., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1543 · Cited by 10
Self-citationRommasi, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-35318-x · Cited by 10
Kruse, M. L., Smyth, E. N., Bowman, L., Gautam, S., Guimaraes, C. M., Nisbett, A. R., Fisher, M. D., Cui, Z. L., Sheffield, K. M., & Kalinsky, K. M. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06993-1 · Cited by 9
DeMichele, A. M., Robert, N. J., Chen, C., Kim, S., Zhang, Z., Lu, D. R., Aguilar, K. M., Wang, Y., Li, B. C., Schneeweiß, S., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00979-1 · Cited by 9
“Similar CDK4/6 inhibitor class effects were observed in the large, multicenter, MONALEESA-7 phase III trial, which evaluated ribociclib or placebo in combination with goserelin and endocrine therapy (AI or tamoxifen) in pre/ perimenopausal women with HR+/HER2− ABC or MBC [31, 32].”
BackgroundFerro, A., Generali, D., Caffo, O., Caldara, A., Lisi, D. D., Dipasquale, M., Lorenzi, M., Monteverdi, S., Fedele, P., & Ciribilli, Y. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.08.002 · Cited by 9
Liu, Y., Dong, K., & Park, C. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2411309 · Cited by 10
“For example, while PALOMA-2 enrolled post-menopausal patients with aBC [7], MONALEESA-7 included premenopausal women [43].”
BackgroundRead, S. H., Quignot, N., Kapnang, R., Comerford, E., Zheng, Y., Gainford, M. C., Sasané, M., Vataire, A. L., Delzongle, L., & Bidard, F. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07201-w · Cited by 10
Yıldırım, H. Ç., Kapar, C., Köksal, B., Seyyar, M., Sanci, P. C., Guliyev, M., Perkin, P., Büyükkör, M., Yaslıkaya, Ş., Majidova, N., et al. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2330835 · Cited by 9
“In metastatic premenopausal patients, only the MONALEESA-7 study has been conducted as a prospective randomized phase 3 study in first-line treat-ment, and there is no phase 3 randomized controlled study of palbociclib [10].”
Michaeli, J. C., Michaeli, T., Trapani, D., Albers, S., Dannehl, D., Würstlein, R., & Michaeli, D. T. (2024) · Breast Cancer · doi:10.1007/s12282-024-01634-x · Cited by 9
Chainitikun, S., Long, J. P., Rodríguez‐Bautista, R., Iwase, T., Tripathy, D., Fujii, T., & Ueno, N. T. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05837-6 · Cited by 9
Self-citationReinert, T., Pellegrini, R. A., & Barrios, C. H. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1081 · Cited by 9
“However, the MONALEESA-7 trial addressing specifically pre- or peri-menopausal patients clearly demonstrated a favourable outcome with the use of ribociclib with clinical and statistically significant gains in PFS and OS [8, 13].”
BackgroundInfluentialKovač, A., Matos, E., Kuhar, C. G., Čakš, M., Ovčariček, T., Mencinger, M., Humar, M., & Borštnar, S. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100201 · Cited by 10
Vasseur, A., Carton, M., Guiu, S., Augereau, P., Uwer, L., Mouret‐Reynier, M., Lévy, C., Eymard, J., Ferrero, J.-M., Leheurteur, M., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.07.014 · Cited by 10
Regional Variations in Clinical Trial Outcomes in Oncology.
Wilson, B. E., Pearson, S., Barton, M., & Amir, E. (2022) · The Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7029 · Cited by 7
Reporting of older subgroups in registration breast cancer trials 2012–2021
Eochagáin, C. M., & Battisti, N. M. L. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07081-0 · Cited by 10
“Three trials, MONALEESA-7 [12], which exclusively addressed pre/peri-menopausal women aged between 18 and 59; TRYPHAENA [13], a parallel non-efficacy/cardiac safety study for the CLEOPATRA trial; and IMMU-132 [14], a basket trial enrolling patients with epithelial cancers of any site (including…”
Background
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.